---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-APN-306"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: APC-APN-306. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 15 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/apc-apn-306"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-APN-306

<a id="heading-3.1.3"></a>

## 3.1.3 APC-APN-306

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Long-term safety of AD109 in participants completing a parent phase 3 trial

> “We have followed up with an open-label extension (OLE) study (NCT06566820) to evaluate the long-term safety of AD109 in OSA by enrolling qualifying participants who completed one of the parent phase 3 trials.”
> “This large OLE study is designed to confirm and extend the safety evidence of the phase 3 SynAIRgy and LunAIRo randomized control trials evaluating the efficacy and safety of AD109 in the treatment of OSA.”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

> “The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.”

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

<a id="topic-3.1.3.1-2"></a>

#### Exploratory objectives: night-to-night variability by ring oximetry and patient-reported outcomes by mobile application

> “In addition, we aimed to assess night-to-night OSA variability with a high-resolution pulse oximetry ring and the OSA burden over time using validated Patient Reported Outcomes (PROs) collected with a mobile application.”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Registry dates and status, last updated May 2025

| Field | Registry entry |
| --- | --- |
| Study start (actual) | “2024-07-03” |
| Primary completion (estimated) | “2026-06-30” |
| Last update posted | “2025-05-13” |

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

<a id="topic-3.1.3.2-2"></a>

#### Completion of the open-label extension in 2026 per the company

> “Both LunAIRo and SynAIRgy trials were completed in 2025 and the OLE trial was completed in 2026.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Phase 3, single-group, open-label continuation protocol

> “A Phase 3 Open Label Continuation Protocol of a Fixed Dose Combination of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea”

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

<a id="topic-3.1.3.3-2"></a>

#### Washout before open-label dosing and serial safety assessments

> “After informed consent and a one week washout, participants will undergo the following dosing regimen, serial assessments and data collection (see enclosed figure).”
> “Optional exploratory data collection involving serial assessments using a ring-worn pulse oximeter and OSA-related PROs were offered to the OLE participants.”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

<a id="topic-3.1.3.3-3"></a>

#### Safety follow-up for up to an additional year after either phase 3 trial

> “Participants completing either of these studies are eligible for an optional open label extension (OLE) study of AD109 in which safety is assessed for up to an additional year”

Source: [Taranto-Montemurro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12490522/)

> “Syneos provided services to us in connection with LunAIRo and SynAIRgy and the OLE that allowed patients to extend their treatment following completion of either Phase 3 protocol.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Completion of a parent phase 3 trial without permanent discontinuation of study drug

> “Completion of APC-APN-304 without permanent discontinuation of IMP.”
> “Completion of APC-APN-305 without permanent discontinuation of IMP.”
> “Participants are excluded from the study if participation would be considered unsafe by the investigator based on the individual's current status.”
> “Participants are excluded from the study if participation would be considered unsafe by the investigator based on concomitant therapies.”

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

> “All participants completing a parent phase 3 trial with continued use of investigational product were eligible for inclusion in the OLE study if considered safe by the study team.”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Open-label fixed-dose combination of aroxybutynin and atomoxetine

> “Open Label AD109”
> “Fixed Dose Combination”

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Incidence of Adverse Events as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Registry primary outcome measures: adverse events, vital sign abnormalities, and concomitant therapy

> “Number of Participants With Adverse Events (AES) and Serious Adverse Events (SAEs)”
> “Number of Participants With Vital Signs Abnormalities”
> “Vital signs that are planned to be assessed include parameters such as weight,heart rate and systolic and diastolic blood pressure.”
> “Number of Participants With Concomitant Therapy (Medication or Devices)”
> “Concomitant therapy with devices (i.e., CPAP) and concomitant medications are other prescription medications, over-the-counter (OTC) drugs or dietary supplements that a study participant takes in addition to the drug under investigation.”
> “through study completion, an average of 1 year”

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

<a id="topic-3.1.3.6.1-2"></a>

##### Safety assessments and exploratory oximetry parameters

> “Safety assessments include continued measurement of vital signs, monitoring and recording of adverse events, serious adverse events, pregnancies, and recording of study or treatment discontinuations.”
> “Oximetry-derived parameters included the oxygen desaturation index based on 4% desaturation, time with oxygen saturation ≤ 90%, and hypoxic burden.”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Planned enrollment

| Field | Registry entry |
| --- | --- |
| Enrollment (estimated) | “1280” |

Source: [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Interim enrollment and uptake of exploratory data collection

> “One hundred and two participants (70% of eligible) have enrolled in the OLE study to date.”
> “Seventy-three participants (72%) also opted-in to the exploratory data collection with 1179 overnight pulse oximetry recordings and 319 PRO questionnaires collected.”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Interim safety conclusion stated without data

> “Data collected to date supports the long-term safety of AD109”

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

- Design: open-label, single-group continuation study with no comparator; the registered primary outcomes are counts of participants with adverse events, vital sign abnormalities, and concomitant therapy.
- Population: eligibility required completion of a parent phase 3 trial without permanent discontinuation of study drug, so participants who stopped study drug in the parent trials were not eligible.
- Status: the registry record (last updated 2025-05-13) lists an estimated enrollment of 1,280 and an estimated primary completion of 2026-06-30, while the prospectus states the trial was completed in 2026.
- Results: the only results are interim data from a 2025 congress abstract, with 102 participants enrolled (70% of eligible). The abstract states that data collected to date support long-term safety without reporting adverse event data, and no baseline, efficacy, patient-reported outcome, or analysis-set information is available.
- Exploratory ring oximetry and mobile-application PROs were optional; 73 participants (72%) opted in.
- Sponsor: the prospectus states that Syneos provided services to the company in connection with the trial.

Source: [Strollo et al. (2025a)](https://academic.oup.com/ajrccm/article/211/Supplement_1/A6934/8338233); [ClinicalTrials.gov NCT06566820](https://clinicaltrials.gov/study/NCT06566820); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
